Preclinical models also revealed in male mice that anti-tumor responses diminished to BRAF/MEKi, associated with elevated androgen receptor (AR) expression in tumors, which promotes melanoma cell proliferation, particularly in testosterone-rich environments. Here, BRAF is linked to melanoma.